Kaleido Biosciences Earnings Estimate

KLDO -  USA Stock  

USD 2.10  0.06  2.78%

Many public companies, such as Kaleido Biosciences, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Kaleido Biosciences' earnings estimates, investors can diagnose different trends across Kaleido Biosciences' analyst sentiment over time as well as compare current estimates against different timeframes.
Kaleido Biosciences is projected to generate -2.34 in earnings per share on the 31st of December 2021. Kaleido Biosciences earnings estimates module stress-tests analyst consensus about projected Kaleido Biosciences EPS (Earning Per Share) to derive its highest and lowest estimates based on its historical volatility. Please see Stocks Correlation.

Kaleido Earnings Estimates 

 
Refresh
The value of Gross Profit is estimated to slide to about 872.4 K. The value of Profit Margin is estimated to slide to -81.29

Kaleido Biosciences Earnings Estimation Breakdown

Calculation of earning per share of Kaleido Biosciences is based on official Zacks consensus of 3 analysts regarding Kaleido Biosciences future annual earnings. Given the historical accuracy of 80.52%, the future earnings per share of Kaleido Biosciences is estimated to be -2.34 with the lowest and highest values of -2.53 and -2.26, respectively. Please note that this consensus of annual earnings estimates for Kaleido Biosciences is an estimate of EPS before non-recurring items and including employee stock options expenses
Current EPS
-2.24
24th of January 2022
-2.53
Lowest
Estimated EPS
-2.34
-2.26
Highest

Kaleido Biosciences Earnings Projection Consensus

Suppose the current estimates of Kaleido Biosciences' value are higher than the current market price of the Kaleido Biosciences stock. In this case, investors may conclude that Kaleido Biosciences is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Kaleido Biosciences' stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyCurrent EPSEPS Estimate for 31st of December 2021

3

80.52%

-2.239

-2.34

Kaleido Biosciences Earnings per Share Projection vs Actual

Actual Earning per Share of Kaleido Biosciences refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Kaleido Biosciences predict the company's earnings will be in the future. The higher the earnings per share of Kaleido Biosciences, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Kaleido Biosciences Estimated Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Kaleido Biosciences, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Kaleido Biosciences should always be considered in relation to other companies to make a more educated investment decision.

Kaleido Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact Kaleido Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-11-01
2021-09-30-0.5357-0.54-0.0043
2021-08-11
2021-06-30-0.5794-0.560.0194
2021-05-04
2021-03-31-0.605-0.580.025
2021-03-03
2020-12-31-0.3984-0.56-0.161640 
2020-11-02
2020-09-30-0.6348-0.65-0.0152
2020-08-04
2020-06-30-0.59-0.590
2020-05-14
2020-03-31-0.6415-0.640.0015
2020-03-02
2019-12-31-0.3366-0.65-0.313493 
2019-10-30
2019-09-30-0.8957-0.740.155717 
2019-08-01
2019-06-30-0.9976-0.830.167616 
2019-05-02
2019-03-31-0.7405-0.680.0605

About Kaleido Biosciences Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Kaleido Biosciences earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Kaleido Biosciences estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Kaleido Biosciences fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for 2022
Accumulated Retained Earnings Deficit-246.8 M-266.2 M
Earning Before Interest and Taxes EBIT-70.9 M-76.5 M
Earnings per Basic Share(2.81) (3.03) 
Earnings per Diluted Share(2.81) (3.03) 
Price to Earnings Ratio(3.36) (3.62) 
Earnings Before Interest Taxes and Depreciation Amortization EBITDA-69.3 M-74.8 M
Earnings before Tax-73.5 M-79.3 M
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts. Kaleido Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 82 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Kaleido Biosciences without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Efficient Frontier Now

   

Efficient Frontier

Plot and analyze your portfolio and positions against risk-return landscape of the market.
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Kaleido Biosciences using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Stocks Correlation. Note that the Kaleido Biosciences information on this page should be used as a complementary analysis to other Kaleido Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Analyst Recommendations module to analyst recommendations and target price estimates broken down by several categories.

Complementary Tools for Kaleido Stock analysis

When running Kaleido Biosciences price analysis, check to measure Kaleido Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kaleido Biosciences is operating at the current time. Most of Kaleido Biosciences' value examination focuses on studying past and present price action to predict the probability of Kaleido Biosciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kaleido Biosciences' price. Additionally, you may evaluate how the addition of Kaleido Biosciences to your portfolios can decrease your overall portfolio volatility.
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Is Kaleido Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kaleido Biosciences. If investors know Kaleido will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kaleido Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Kaleido Biosciences is measured differently than its book value, which is the value of Kaleido that is recorded on the company's balance sheet. Investors also form their own opinion of Kaleido Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Kaleido Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kaleido Biosciences' market value can be influenced by many factors that don't directly affect Kaleido Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kaleido Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Kaleido Biosciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kaleido Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.